Neostigmine is a cholinesterase inhibitor whose mechanism of action is to inhibit cholinesterase to cause a large buildup of acetylcholine, which excites the N2 receptor in skeletal muscle, leading to contraction of the skeletal muscle and an increase in the muscle tone of smooth and skeletal muscle. Clinically, Neostigmine can be used for the treatment of myasthenia gravis as well as postoperative intestinal flatulence and urinary retention and other diseases. Patients are advised to use the drug in strict accordance with the instructions of the drug or the doctor’s prescription, and it is strictly prohibited to change the dosage or the duration of use without authorization in the process of using the drug.